000			01685nam a22002537a 4500
999			_c8083 _d8083
001			CH 2010 0007
003			PILC
005			20240720152613.0
008			160505b2010 xxu||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aenglish
050			_aCH 2010 0007
245			_aSevere pyridostigmine toxicity : _ba case report / _cJoan A. Serrano.
260			_aFairview, Quezon City: _bDepartment of Child Health, FEU-NRMF, _c2010.
300			_a18 pages: _billustrations, tables; _c(in folder)
336			_atext _2rdacontent
337			_aunmediated _2rdamedia
338			_avolume _2rdacarrier
504			_aIncludes appendices and bibliographical references.
520			_aAbstract: A 13 months old, female diagnosed with congenital myasthenia gravis at 9 months maintained on Pyridostigmine at 15 mg/paper tablet taken 5 times a day with sudden difficulty of breathing, drooling of saliva and seizure. Patient was admitted at the pediatric intensive care unit and inderwent atropinization. Pyridostigmine toxicity in myasthenia gravis is a rare condition since the drug is given to patients based on their signs and symptoms and computed according to their age and weight. Diagnosis can be made based on the presenting clinical signs and symptoms supported by an assay. However, in this case, pyridostigmine assay is available in our country thus, diagnostic dilemma sets in. Such incident warrants investigation and prompt intervention. At present, no standard mode of treatment was established to follow when such case is encountered.
521			_aRESDCH
700			_aSerrano, Joan A., MD. _eauthor
942			_2lcc _cRU